Alcon Laboratories, Inc.

Alcon Manufacturing, Ltd.

Novartis Ag

Alcon, Inc.

Synthelabo

Louis DeSantis, Jr

Verney L Sallee

Michael A Kapin

Thomas R Dean

Billie M York

John E Bishop

Robert J Collier, Jr

Jesse Albert May

Paul W Zinke

Iok-Hou Pang

Rajni Jani

Salomon Z Langer

Manoj L Maniar

Robert J Adamski

Marsha A McLaughlin

Compositions and methods for treating disorders of the outer retina with &#x3b2;-adrenoceptor antagonists are disclosed.

Use of beta-adrenoceptor antagonists for the manufacture of a medicament of the treatment of disorders of the outer retina

The invention is directed to the use of &#x3b2;-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina.

Use of &#x3b2;-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina

Methods for treating persons with glaucoma or ocular hypertension with glutamate antagonists and IOP-lowering compounds are disclosed.

Combination therapy for treating glaucoma

Disclosed is the use of cloprostenol and fluprostenol analogues in combination with carbonic anhydrase inhibitors for the treatment of glaucoma and ocular hypertension and ophthalmic compositions therefor.

Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension

Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.

Brinzolamide and brimonidine for treating glaucoma

The invention provides pharmaceutical compositions containing calpain inhibitors and methods of using these calpain inhibitors to prevent or ameliorate ocular neural tissue disease or damage.

Use of calpain inhibitors to treat ocular neural pathology

Brinzolamide and brimonidine for treating ocular conditions

Methods for treating persons with glaucoma or ocular hypertension with polyamine antagonists and an IOP-lowering compounds are also disclosed.

Combinations of at least one clonidine derivative and at least one prostaglandin are used to treat glaucoma and ocular hypertension without some of the side effects typically associated with topical administration of prostaglandins.

Combinations of prostaglandins and clonidine derivatives for the

9-Halo-13,14-dihydroprostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.

Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and

Polyamine antagonists are found to be effective in preventing or reducing visual field loss associated with glaucoma. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.

Use of polyamine antagonists for the treatment of glaucoma

The use of certain dopaminergic compounds for controlling elevations of intraocular pressure is disclosed. The compounds are ergoline derivatives. The most preferred compound is cabergoline. The compounds have been found to produce a significant reduction of intraocular pressure.

Use of cabergoline and related ergoline derivatives for controlling

9-Haloprostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.

Use of certain 9-haloprostaglandins to treat glaucoma and ocular

Pharmaceutical compositions useful in ophthalmic surgery are described. The compositions include one or more polyamine antagonists, and are useful for preventing or treating excitotoxicity associated with ophthalmic surgery. Methods of using the compositions in connection with ophthalmic surgical procedures are also described.

Growing community of inventors

Fort Worth, TX, United States of America

Louis DeSantis, Jr